Wire · opportunities
Ad Hoc Analysis Supports Contributions of Both Enfortumab Vedotin and Pembrolizumab in ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 October 2026 · Fusion42 review
An ad hoc analysis from the phase 3 KEYNOTE-905/EV-303 trial shows that the combination of enfortumab vedotin and pembrolizumab improves event-free survival and overall survival compared to surgery alone for patients with muscle-invasive bladder cancer (MIBC) ineligible for cisplatin. This supports previous FDA approvals and an indication expansion for these therapies.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can now position your biotech pipeline to include enfortumab vedotin and pembrolizumab combinations as validated perioperative treatments for MIBC beyond cisplatin-eligible groups. Expect shifting standards of care and new market avenues in bladder cancer therapy.
◆ Coverage
1 source · 24 Oct 2026
◆ Related on Wire
◆ Topics